Gensaic与诺和诺德达成3.54亿美元协议，推进心血管代谢疾病精准治疗相关的帖子：-动脉网

Gensaic Partners with Novo Nordisk in $354M Deal to Advance Precision Therapies for Cardiometabolic Diseases Related posts:

GeneOnline 等信源发布 2025-03-04 12:54



可切换为仅中文







by Bernice Lottering

作者：伯尼斯·洛特林

Share To

分享到

Gensaic partners with Novo Nordisk in a $354M deal to develop precision therapies for cardiometabolic diseases. Image: Freepik.

Gensaic与诺和诺德达成3.54亿美元的合作协议，共同开发针对心代谢疾病的精准疗法。图片来源：Freepik。

ensaic, Inc. has entered a

恩赛克公司已经进入了一个

collaboration

协作

with Novo Nordisk to explore next-generation precision therapies aimed at treating cardiometabolic diseases. The partnership, which could be worth up to $354 million, includes upfront payments, development and commercial milestone payments, and tiered royalties per target. Additionally, Novo Nordisk will reimburse research and development costs and participate in a future financing round..

与诺和诺德合作，探索针对心代谢疾病治疗的下一代精准疗法。这项合作价值可能高达3.54亿美元，包括预付款、开发和商业化里程碑付款以及每个靶点的阶梯式专利使用费。此外，诺和诺德将补偿研发成本，并参与未来的融资轮次。

Leveraging Novo Nordisk’s Expertise and Gensaic’s FORGE Engine for Tissue-Selective Intracellular Delivery of Therapeutic Molecules in Cardiometabolic Diseases

利用诺和诺德的专业知识和Gensaic的FORGE引擎，实现治疗分子在心脏代谢疾病中的组织选择性细胞内递送。

Privately-held

私营的

Gensaic

基因赛克

, a biotech company based in Cambridge, USA, has announced a potentially lucrative license and discovery partnership with Denmark’s Novo Nordisk (

，一家位于美国剑桥的生物技术公司，宣布与丹麦的诺和诺德（Novo Nordisk）达成一项可能带来丰厚利润的许可及发现合作伙伴关系。

NVO

). The collaboration combines Novo Nordisk’s extensive expertise in therapeutics and drug development with Gensaic’s

）。该合作结合了诺和诺德在治疗学和药物开发方面的广泛专业知识与Gensaic的

FORGE engine

锻造引擎

, a proprietary technology for tissue-selective intracellular delivery of therapeutic molecules. The partnership aims to discover novel tissue-targeting ligands and develop therapeutic candidates for treating cardiometabolic diseases through undisclosed targets.

，一种用于组织选择性细胞内递送治疗分子的专有技术。该合作旨在发现新的组织靶向配体，并通过未公开的靶点开发治疗心脏代谢疾病的候选药物。

Gensaic is set to receive up to $354 million through upfront payments, development milestones, and commercial milestones for each target, along with tiered royalties. Novo Nordisk will also cover R&D costs, participate in a future financing round, and appoint an executive to Gensaic’s board as a non-voting observer.

Gensaic将为每个靶点获得高达3.54亿美元的预付款、开发里程碑和商业化里程碑，以及阶梯式特许权使用费。诺和诺德还将承担研发成本，参与未来的融资轮次，并委派一名高管作为非投票观察员加入Gensaic董事会。

In the collaboration, Gensaic will discover new protein ligands, while Novo Nordisk will retain the rights to further develop and leverage these ligands. The agreement includes Novo Nordisk’s license and option rights to advance multiple therapeutic programs through research, development, and commercialization..

在合作中，Gensaic将发现新的蛋白质配体，而诺和诺德将保留进一步开发和利用这些配体的权利。该协议包括诺和诺德通过研究、开发和商业化推进多个治疗项目的许可和选择权。

Optimizing Protein Interactions through Machine-Guided Design for Targeted Intracellular Delivery

通过机器引导设计优化蛋白质相互作用以实现靶向细胞内递送

This partnership aims to discover novel tissue-targeting ligands and develop therapeutic candidates for treating cardiometabolic conditions through undisclosed targets. Essentially, Gensaic aims to enable the selective delivery of any therapeutic payload to specific tissues of interest.

该合作伙伴关系旨在发现新的组织靶向配体，并通过未公开的靶点开发治疗心脏代谢疾病的候选药物。本质上，Gensaic的目标是实现将任何治疗载荷选择性递送到特定目标组织。

Tissue targeting plays a crucial role in the development of precision medicines by allowing drugs to be delivered to specific organs or cell types, yet challenges remain in targeting beyond the liver. Gensaic’s Functional Optimization by Recursive Genetic Evolution (FORGE) technology, which integrates protein evolution with machine-guided design, addresses these challenges by optimizing protein interactions that dictate how therapeutic molecules travel within the body..

组织靶向在精准药物的开发中起着至关重要的作用，它使药物能够被递送到特定器官或细胞类型，但在肝外靶向上仍存在挑战。Gensaic 的功能性优化递归遗传进化 (FORGE) 技术将蛋白质进化与机器引导设计相结合，通过优化决定治疗分子在体内传输方式的蛋白质相互作用来应对这些挑战。

Gensaic’s CEO, Dr. Lavi Erisson, expressed that the partnership with Novo Nordisk strengthens the potential of Gensaic’s technology and accelerates the development of their innovative pipeline. Novo Nordisk’s deep understanding of therapeutic markets complements Gensaic’s scientific capabilities, enabling the pursuit of previously challenging therapeutic targets while enhancing efficacy and minimizing side effects..

Gensaic公司首席执行官拉维·埃里克森博士表示，与诺和诺德的合作增强了Gensaic技术的潜力，并加速了其创新研发管线的开发。诺和诺德对治疗市场的深刻理解与Gensaic的科研能力相辅相成，使得追求以往具有挑战性的治疗靶点成为可能，同时提高了疗效并减少了副作用。

Uli Stilz, Head of Novo Nordisk’s Bio Innovation Hub, said “Tissue targeting holds immense potential – not only in terms of the modalities that can be utilized, but also for the range of diseases it can address. Gensaic’s technology brings a novel approach, with the ability to screen tissue targeting ligands in an unbiased way.

诺和诺德生物创新中心负责人乌利·斯蒂尔茨表示：“组织靶向具有巨大的潜力——不仅在于可以利用的模式，还在于它能够应对的疾病范围。Gensaic的技术带来了全新的方法，能够以无偏见的方式筛选组织靶向配体。”

By coupling Gensaic’s technology with our team’s deep understanding of disease and drug development, we have the potential to reach challenging targets, while increasing efficacy and reducing potential side effects.”.

通过将Gensaic的技术与我们团队对疾病和药物开发的深刻理解相结合，我们有潜力攻克具有挑战性的靶点，同时提高疗效并减少潜在副作用。

Novo Expands Focus on Intracellular Targeting with Strategic Acquisitions and Partnerships

诺沃通过战略性收购和合作伙伴关系，扩大了对细胞内靶向的关注。

In 2021, Novo intensified its focus on intracellular targets by

2021年，诺和加大了对细胞内靶点的关注力度，

acquiring

获取

Dicerna Pharmaceuticals, a leader in RNA interference (RNAi) technology. Marcus Schindler, Novo’s Chief Scientific Officer, emphasized the need for advanced intracellular technologies,

Dicerna Pharmaceuticals是RNA干扰（RNAi）技术的领导者。诺和的首席科学官马库斯·辛德勒强调了对先进的细胞内技术的需求，

stating

声明

, “We do not want to be limited too much when we see novel targets, when we see exciting biology.”

“当我们看到新的靶点时，当我们看到令人兴奋的生物学现象时，我们不希望受到太多限制。”

Novo’s acquisition of Dicerna provided access to RNAi-based therapies, initially focusing on liver-specific targets and later expanding to other organs. The collaboration with Gensaic further strengthens this strategy by offering a novel tissue-selective delivery approach. Novo’s interest in Gensaic was piqued at the company’s 2022 Golden Ticket event, where Uli Stilz, Head of Novo Nordisk’s Bio Innovation Hub, served as a .

诺和收购迪赛纳获得了基于RNAi的治疗方法，最初专注于肝脏特异性靶点，后来扩展到其他器官。与Gensaic的合作通过提供一种新颖的组织选择性递送方法进一步强化了这一战略。诺和对Gensaic的兴趣在该公司2022年的“金票”活动上被激发，当时诺和诺德生物创新中心负责人乌利·斯蒂尔茨担任了该活动的评委。

judge

法官

. This partnership enhances Novo’s ability to deliver therapies precisely to target tissues, advancing their commitment to innovative protein-based treatments for complex diseases.

这一合作增强了诺和公司精确向目标组织递送治疗药物的能力，推动了他们致力于为复杂疾病提供创新的蛋白质疗法。

Global Landscape of Protein Therapies: Key Players and Their Contributions

蛋白质疗法的全球格局：主要参与者及其贡献

Protein therapies, also known as biologics, have become a major force in modern medicine. These therapies use proteins or peptides to treat a variety of diseases. Some of the most commonly used protein therapies include monoclonal antibodies (mAbs), insulin, enzyme replacement therapies (ERTs), and blood factor therapies.

蛋白质疗法，也被称为生物制剂，已成为现代医学的一股重要力量。这些疗法利用蛋白质或肽来治疗各种疾病。一些最常用的蛋白质疗法包括单克隆抗体 (mAbs)、胰岛素、酶替代疗法 (ERTs) 和凝血因子疗法。

Monoclonal antibodies like Humira (adalimumab), Herceptin (trastuzumab), and Keytruda (pembrolizumab) are widely used to treat autoimmune diseases, cancer, and other conditions. Insulin therapies like Lantus (insulin glargine) and Humalog (insulin lispro) are essential for managing diabetes. ERTs such as Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta) are life-saving treatments for genetic disorders like Gaucher and Fabry diseases.

像修美乐（阿达木单抗）、赫赛汀（曲妥珠单抗）和Keytruda（派姆单抗）这样的单克隆抗体被广泛用于治疗自身免疫疾病、癌症及其他病症。像来得时（甘精胰岛素）和优泌乐（赖脯胰岛素）这样的胰岛素疗法对糖尿病的管理至关重要。ERTs如Cerezyme（伊米苷酶）和Fabrazyme（阿加糖酶β）是用于治疗戈谢病和法布里病等遗传性疾病的救命药物。

Blood factor therapies, including Advate (recombinant factor VIII), help patients with bleeding disorders like hemophilia..

血液因子疗法，包括Advate（重组因子VIII），帮助患有血友病等出血性疾病的患者。

The production of these therapies is largely concentrated in key countries, with the United States, Switzerland, Denmark, and Germany leading the charge. In the U.S., companies such as AbbVie, Genentech (a Roche subsidiary), Eli Lilly, and Amgen play major roles in developing monoclonal antibodies, insulin treatments, and hormone therapies.

这些疗法的生产主要集中于少数关键国家，其中美国、瑞士、丹麦和德国处于领先地位。在美国，艾伯维、基因泰克（罗氏子公司）、礼来和安进等公司在单克隆抗体、胰岛素治疗和激素疗法的开发中扮演着重要角色。

Novo Nordisk, based in Denmark, is a global leader in insulin and hormone-based treatments. Sanofi and Genzyme in France are recognized for their pioneering work in enzyme replacement therapies. German companies like Bayer and Merck are at the forefront of hormone treatments and blood factor therapies, including recombinant therapies for hemophilia..

诺和诺德总部位于丹麦，是胰岛素和激素治疗领域的全球领导者。法国的赛诺菲和健赞因其在酶替代疗法方面的开创性工作而受到认可。德国的拜耳和默克等公司在激素治疗和凝血因子疗法（包括血友病的重组疗法）方面处于领先地位。

Additionally, CAR-T cell

此外，CAR-T细胞

therapies have become a breakthrough for cancer treatment

疗法已成为癌症治疗的突破性进展

. Therapies like Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) offer new hope for cancer patients. These therapies are developed by companies like Novartis, Kite Pharma, and Bristol-Myers Squibb in the U.S., and Roche in Switzerland. The global distribution of these therapies is made possible by biotech hubs in the U.S., Europe, and Asia, ensuring access to biologics that are reshaping the healthcare landscape..

像Kymriah（替沙基仑赛）和Yescarta（阿基仑赛）这样的疗法为癌症患者带来了新的希望。这些疗法由诺华、Kite Pharma和百时美施贵宝等美国公司，以及瑞士的罗氏公司开发。这些疗法的全球分发得益于美国、欧洲和亚洲的生物技术中心，确保了能够改变医疗保健格局的生物制剂的可及性。